Skip to main content
Premium Trial:

Request an Annual Quote



Predicting the progression of a patient's cancer can often help an oncologist determine the Goldilocks course of treatment — not too harsh, not too light, but just right. Researchers at the Einstein Medical Center in Pennsylvania are using a gene test from Genomic Health to help them determine if women with ductal carcinoma in situ need aggressive treatment or not, reports USA Today's Liz Szabo. The test analyzes 12 tumor genes and can help predict which cases will be aggressive and which will be slow-growing. The more aggressive cancers often require both surgery and radiation to treat, while the slow-growing kind can often be treated with surgery alone, Szabo says. According to a study done by the Einstein Medical Center researchers, the gene test shows that about 75 percent of women won't need radiation to control their DCIS. Genomic Health plans to make the DCIS test available by the end of the year, Szabo says. Although it comes with a rather hefty $4,175 price tag, experts say it could still save patients money by helping them avoid radiation treatments, which are far more expensive.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.